Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Total Liabilities (2020 - 2025)

Historic Total Liabilities for Arcutis Biotherapeutics (ARQT) over the last 6 years, with Q3 2025 value amounting to $212.9 million.

  • Arcutis Biotherapeutics' Total Liabilities fell 2415.6% to $212.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $212.9 million, marking a year-over-year decrease of 2415.6%. This contributed to the annual value of $191.3 million for FY2024, which is 2427.8% down from last year.
  • As of Q3 2025, Arcutis Biotherapeutics' Total Liabilities stood at $212.9 million, which was down 2415.6% from $213.5 million recorded in Q2 2025.
  • In the past 5 years, Arcutis Biotherapeutics' Total Liabilities ranged from a high of $280.7 million in Q3 2024 and a low of $18.4 million during Q2 2021
  • For the 5-year period, Arcutis Biotherapeutics' Total Liabilities averaged around $182.0 million, with its median value being $213.5 million (2025).
  • Per our database at Business Quant, Arcutis Biotherapeutics' Total Liabilities soared by 89171.28% in 2022 and then crashed by 2427.8% in 2024.
  • Arcutis Biotherapeutics' Total Liabilities (Quarter) stood at $110.5 million in 2021, then surged by 116.97% to $239.7 million in 2022, then increased by 5.43% to $252.7 million in 2023, then decreased by 24.28% to $191.3 million in 2024, then grew by 11.27% to $212.9 million in 2025.
  • Its Total Liabilities stands at $212.9 million for Q3 2025, versus $213.5 million for Q2 2025 and $201.4 million for Q1 2025.